Skip to main content
main-content

The independent medical news service

Prostate cancer

29-05-2020 | Oncology | News | Article

FDA approves rucaparib, olaparib for mutated metastatic CRPC

Read more on these decisions

27-05-2020 | Oncology | Highlight | Article

Data question ADT omission when using EBRT plus brachytherapy boost

Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.

22-05-2020 | Oncology | News | Article

Data reinforce HSD3B1 variant link to poor mCRPC outcome

Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.

13-05-2020 | Oncology | News | Article

EMA supports hybrid cabazitaxel formulation for mCRPC

Click here to read more

07-05-2020 | Oncology | News | Article

Link between ADT and reduced COVID-19 risk proposed

An analysis of Italian patients suggests a potential protective role of androgen deprivation therapy against SARS-CoV-2 infection.

28-04-2020 | Oncology | News | Article

IMbassador250: Atezolizumab–enzalutamide strikes out in mCRPC

The phase 3 IMbassador250 trial has failed to show any significant improvement in metastatic castration-resistant prostate cancer outcomes with the addition of atezolizumab to enzalutamide.

02-04-2020 | Oncology | News | Article

SABR benefits men with oligometastatic prostate cancer

Stereotactic ablative radiotherapy is associated with a significantly lower risk for disease progression at 6 months relative to observation in men with oligometastatic prostate cancer, phase 2 study data show.

13-03-2020 | Oncology | News | Article

Genetic link to poorer outcomes in men with low-volume metastatic CSPC

Prospective data now confirm that White men with low-volume metastatic castration-sensitive prostate cancer who have the adrenal-permissive HSD3B1 genotype have poorer outcomes than those with the adrenal-restrictive genotype.

09-03-2020 | Oncology | News | Article

Predictive prostate cancer models may identify potential candidates for active surveillance

US researchers have developed predictive models that could help identify men with prostate cancer who are likely to undergo pathologic downgrading after radical prostatectomy and therefore may be suitable candidates for active surveillance.

05-03-2020 | Oncology | News | Article

Combining MRI-targeted, systematic biopsy best for prostate cancer diagnosis

A combined approach using both MRI-targeted and systematic biopsy provides improved diagnostic accuracy for the detection of prostate cancer versus either strategy alone, say the Trio researchers.

26-02-2020 | Oncology | News | Article

Pembrolizumab–enzalutamide combination has ‘modest activity’ in mCRPC

The addition of pembrolizumab to enzalutamide has “modest activity” against metastatic castration-resistant prostate cancer that has become resistant to enzalutamide, say the KEYNOTE-199 researchers.

25-02-2020 | Oncology | News | Article

STAMPEDE: Better QoL with abiraterone than docetaxel in prostate cancer

Abiraterone is associated with improved quality of life relative to docetaxel in men with hormone-naïve prostate cancer, shows an analysis of contemporaneously randomized participants of the STAMPEDE trial.

19-02-2020 | Oncology | News | Article

COSMIC-021: Cabozantinib–atezolizumab duo promising for mCRPC

The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.

14-02-2020 | Oncology | News | Article

CARD: Favorable metastatic CRPC PROs observed with cabazitaxel

The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.

14-02-2020 | Oncology | News | Article

Long-term CHHiP data further support hypofractionated radiotherapy for prostate cancer

The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.

14-02-2020 | Oncology | News | Article

​​​​​​​STOMP 5-year results confirm potential of metastasis-directed therapy in prostate cancer

Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.

11-02-2020 | Oncology | News | Article

Incorporating genetic risk may help personalize prostate cancer screening strategies

Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.

04-02-2020 | Oncology | Highlight | News

Darolutamide receives positive EMA decision for nonmetastatic CRPC

Click through for more information

03-02-2020 | Oncology | News | Article

PROs support use of hypofractionated radiation in nonmetastatic prostate cancer

Real-world data show comparable patient reported functional outcomes and health-related quality of life between nonmetastatic prostate cancer patients who were treated with moderately hypofractionated or conventionally fractionated radiation therapy.

24-01-2020 | Oncology | News | Article

Healthy older men may benefit from prostate cancer screening

The risk for clinically significant prostate cancer rises with age, report researchers who believe that this should be taken into account in the optimization of screening practices.

Image Credits